Table 2.
Immune molecules and antimicrobial activity in cervicovaginal lavage samples.
| Variable (median [IQR]) | Non-HR-HPV (n=79) | HR-HPV (n=41) | HPV-16 (n=8) | p-value |
|---|---|---|---|---|
| Protein (log10 μg/mL) mean ± SD | 2.33±0.3 | 2.37±0.37 | 2.45±0.31 | 0.54 |
| IL-1α (pg/mL) | 62.2 [21.9–235.9] | 97.2 [36.3–275] | 195.7 [102.6–1234.1] | 0.03 |
| IL-1β (log10 pg/mL) | 0.43±0.69 | 0.57±0.82 | 0.85±1.09 | 0.27 |
| IL-1ra (pg/mL) | 6026.2 [2975.2–8855.8] | 6446.0 [4516.6–8319] | 8644.1 [7414.1–10000] | 0.15 |
| TNF, n (%) | 38 (50%) | 21 (52.5%) | 7 (87.5%) | 0.13 |
| IL-6, n (%) | 42 (55.3%) | 27 (67.5%) | 7 (87.5%) | 0.13 |
| IL-2, n (%) | 9 (14.8%) | 8 (27.6%) | 1 (20%) | 0.24 |
| IL-17, n (%) | 45 (64.3%) | 19 (51.4%) | 6 (75%) | 0.30 |
| IFN-α2, n (%) | 0 (0%) | 2 (6.9%) | 0 (0%) | 0.19 |
| IFN-γ (pg/mL), | 0.53 [0.27–1.03] | 0.71 [0.41–1.63] | 1.26 [0.53–2.73] | 0.15 |
| IL-8 (log10 pg/mL) | 2.45±0.75 | 2.34±0.75 | 2.91±0.8 | 0.15 |
| MIP-1α n (%) | 47 (61.8%) | 18 (45%) | 4 (50%) | 0.24 |
| MIP-1β n (%) | 24 (31.6%) | 9 (22.5%) | 2 (25%) | 0.62 |
| RANTES, n (%) | 41 (54%) | 20 (50%) | 5 (62.5%) | 0.80 |
| IgA (ng/mL) | 1340 [411–3136] | 1421 [412–4139] | 3084.5 [503.5–4126.5] | 0.60 |
| IgG (ng/mL) | 8262.5 [2807–16968] | 11522 [4926–19125] | 9509 [5008.5–41907] | 0.50 |
| Elafin (ng/mL) | 103.9 [27.7–2113.4] | 43.9 [17.6–190.7] | 86.8 [54.6–475.7] | 0.24 |
| Lactoferrin (ng/ml) | 409.5 [115–959.7] | 334.1 [50–694.7] | 1000.6 [145–3385.1] | 0.43 |
| SLPI (pg/mL) | 59808 [11246–175179] | 66402 [3750–266049] | 32120 [3750–100875] | 0.58 |
| HNP1–3 (log10pg/mL) | 5.07±0.56 | 4.86±0.69 | 5.05±0.85 | 0.22 |
| HBD1 (pg/mL) | 495.6 [167–2179.9] | 503 [210.5–2317.9] | 484.2 [253–654.1] | 0.86 |
| HBD2 (pg/mL) | 387.6 [107.4–1610.5] | 812.9 [145.5–2349.1] | 1794.0 [962.6–6261.9] | 0.049 |
| HBD3, n (%) | 49 (63.6%) | 27 (65.9%) | 4 (50%) | 0.66 |
| E. coli inhibition (%) | 14 [2–32] | 10 [−7–31] | −4 [−19–30.5] | 0.19 |
| HSV inhibition (%) | 20 [6–44] | 29 [2–45] | 18 [12–26] | 0.73 |
| HIVBaL inhibition (%) | 60.3 [29.5–90] | 48 [9–80.5] | −18.2 [−125.8–57.2] | 0.03 |
| HIVIIIb inhibition (%) | 88.25 [71–98] | 84.7 [27–96.7] | 57.8 [22.3–85] | 0.03 |
CVL IL-6, IFN-α2, MIP-1α, MIP-1β, RANTES, IL-2, TNF, IL-17, and HBD-3 with > 25% of samples below the lower limit of detection (LLOD) were dichotomized at the LLOD and are presented as n (%) with detectable levels.